{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '4', 'TREATMENT(S)', '4.1', 'Identification of Investigational Product(s)', '4.1.1', 'Study Drug(s)', 'The investigational product, EV (ASG-22CE), is a sterile, preservative-free, white to off-', 'white lyophilized powder to be reconstituted for intravenous administration. The', 'investigational product is supplied by Astellas in single-use glass vials containing 30 mg EV', '(ASG-22CE) in each vial. The investigational product should be stored at 2-8\u00b0C. Details of', 'investigational product receipt, labeling, storage and preparation are provided in a', 'supplemental pharmacy guide.', '4.1.2 Comparative Drug(s)', 'Comparative drugs will be supplied by the responsible site pharmacy of each investigational', 'site. If the site is unable to procure or utilize local supplies for the comparative drug, supplies', 'may be provided centrally by the sponsor as applicable. Sites are permitted to utilize generic', 'docetaxel and paclitaxel that is approved by the respective regulatory authority. Refer to', 'product labels for docetaxel, paclitaxel and vinflunine for storage & handling conditions and', 'caution statements.', 'Please refer to [Section', '5.1 Dosing and Administration of Study Drug(s) and Other', 'Medication(s)] for specific dosing instructions.', 'For sponsor supplied comparative drug, details of product receipt, labeling, storage and', 'preparation are provided in a supplemental pharmacy guide.', '4.2', 'Packaging and Labeling', 'EV (ASG-22CE) used in this study will be prepared, packaged, and labeled under the', \"responsibility of qualified staff at APGD-Astellas US Technologies (AUST) or sponsor's\", \"designee in accordance with APGD-AUST or sponsor's designee Standard Operating\", 'Procedures (SOPs), Good Manufacturing Practice (GMP) guidelines, ICH GCP guidelines,', 'and applicable local laws/regulations.', 'Each carton and vial will bear a label conforming to regulatory guidelines, GMP and local', 'laws and regulations that identifies the contents as investigational drug.', 'Where supplied by the Sponsor, the comparative drug(s) used in this study will be labeled', \"under the responsibility of APGD-AUST or sponsor's designee in accordance with APGD-\", \"AUST or sponsor's designee SOPs, GMP guidelines, ICH GCP guidelines, and applicable\", 'local laws/regulations.', \"A qualified person of Astellas Pharma Europe B.V. (APEBV) or sponsor's designee will\", 'perform the final release of the medication according to the requirements of the EU Directive', '2003/94/EC annex 13.', '14 Sep 2020', 'Astellas', 'Page 53 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '4.3', 'Study Drug Handling', 'Current ICH GCP Guidelines require the investigator to ensure that study drug deliveries', 'from the sponsor are received by the investigator/or designee and that:', 'such deliveries are recorded,', 'study drug is handled and stored according to labeled storage conditions,', 'study drug with appropriate expiry/retest and is only dispensed to study subjects in', 'accordance with the protocol, and', 'any unused study drug is returned to the sponsor or standard procedures (reviewed and', 'approved by Astellas) for the alternative disposition of unused study drug are followed.', 'The head of the study site or the study drug storage manager should take accountability of the', 'study drugs as follows:', 'The study drug storage manager should store and take accountability of the study drugs', 'in conforming to the procedures for handling the study drugs written by the sponsor.', \"The study drug storage manager should prepare and retain records of the study drug's\", 'receipt, the inventory at the study site, the use by each subject, and the return to the', 'sponsor or alternative disposal of unused study drugs. These records should include', 'dates, quantities, batch/serial numbers, expiration dates (if applicable), and the unique', 'code numbers assigned to the study drugs and subjects.', 'The study drug storage manager should prepare and retain records that document', 'adequately that the subjects were provided the doses specified by the protocol, and', 'reconcile all the study drugs supplied from the sponsor.', '4.4', 'Blinding', 'This is an open label study.', 'Although the study is an open label study, to maintain trial integrity, analyses or summaries', 'by randomized treatment assignment or actual treatment assignment will be limited and', 'documented while the study is ongoing and before the primary hard lock. Interim analysis', 'will be conducted externally by independent data analysis center (IDAC). Details will be', 'included in SAP.', '4.5', 'Assignment and Allocation', 'Subjects will be randomized in a 1:1 ratio to a treatment arm according to the randomization', 'schedules through Interactive Response Technology (IRT). All subjects who meet the', 'eligibility criteria will be randomized. The site personnel will dispense the treatment', \"according to the IRT system's assignment. Specific procedures for randomization through the\", 'IRT are contained in the study procedures manual. Investigators must select one treatment', 'among the Arm B options before randomization occurs to be used in the event that the', 'subject is randomized to the Arm B. Within the control arm, the overall proportion of', 'subjects receiving vinflunine will be capped at approximately 35%.', '14 Sep 2020', 'Astellas', 'Page 54 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}